Hospital
Community Memorial Hospital
Community Memorial Hospital was paid $7.29M by Medicaid between Jan 2018 and Nov 2024, across 139 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoCOMMUNITY MEMORIAL HOSPITAL
HAMILTON, NY 13346
HAMILTON, NY 13346
33aNPI1992707608assigned 08/12/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$7.29M
24GClaims143,034
24DCodes billed139
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,746 | $108K | |
| 2019 | 9,548 | $313K | |
| 2020 | 20,626 | $590K | |
| 2021 | 27,287 | $934K | |
| 2022 | 30,390 | $2.74M | |
| 2023 | 31,069 | $1.73M | |
| 2024incomplete | 21,368 | $883K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 7,359 | 7,107 | $1.62M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 16% | 4,283 | 4,178 | $1.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.3% | 3,801 | 3,660 | $607K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 7,835 | 7,529 | $538K |
| 80053 | Comprehensive metabolic panel | 7.0% | 9,991 | 9,003 | $513K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.8% | 3,468 | 3,368 | $351K |
| 36415 | Collection of venous blood by venipuncture | 3.9% | 5,131 | 4,099 | $282K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 895 | 883 | $253K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.3% | 1,079 | 995 | $239K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.1% | 1,569 | 1,536 | $155K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 2,856 | 2,675 | $143K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 974 | 950 | $140K |
127 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 914 | $97K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 298 | $93K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 741 | $93K |
| 81025 | <1% | 1,238 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,261 | $61K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 615 | $57K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 156 | $51K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 519 | $47K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 516 | $47K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,360 | $42K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,179 | $36K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 364 | $34K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,124 | $33K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 387 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,844 | $30K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 341 | $29K |
| 80061 | Lipid panel | <1% | 3,886 | $28K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,434 | $25K |
| 99051 | <1% | 3,101 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 326 | $18K |
| 84439 | <1% | 1,807 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 339 | $17K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 79 | $17K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 101 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,933 | $15K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,690 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,983 | $12K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,013 | $11K |
| 87070 | <1% | 1,453 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 312 | $10K |
| 83880 | <1% | 67 | $10K | |
| 82607 | <1% | 662 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,350 | $8K |
| 29125 | <1% | 42 | $8K | |
| 90686 | <1% | 1,515 | $8K | |
| 80076 | <1% | 887 | $7K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 429 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $7K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 66 | $7K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 638 | $6K |
| 96127 | <1% | 1,152 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,042 | $6K |
| 87081 | <1% | 1,224 | $6K | |
| 73610 | <1% | 351 | $6K | |
| 87428 | <1% | 133 | $5K | |
| 83550 | <1% | 1,055 | $5K | |
| 84484 | <1% | 1,692 | $5K | |
| 81003 | <1% | 4,016 | $5K | |
| 83655 | <1% | 391 | $5K | |
| 83690 | <1% | 1,836 | $5K | |
| 83735 | <1% | 1,721 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 240 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 691 | $4K |
| 36000 | <1% | 189 | $4K | |
| 86140 | <1% | 1,039 | $4K | |
| 82746 | <1% | 337 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $4K |
| 87186 | <1% | 942 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 87 | $4K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $4K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 125 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,918 | $3K |
| 84153 | <1% | 175 | $3K | |
| 85610 | <1% | 1,116 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 975 | $3K |
| 76641 | <1% | 110 | $3K | |
| 82728 | <1% | 217 | $3K | |
| 85652 | <1% | 1,231 | $3K | |
| 97161 | <1% | 15 | $3K | |
| 82570 | <1% | 423 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 327 | $2K |
| 87077 | <1% | 390 | $2K | |
| 86900 | <1% | 85 | $2K | |
| 82043 | <1% | 358 | $2K | |
| 73630 | <1% | 185 | $2K | |
| 82248 | <1% | 590 | $2K | |
| 85730 | <1% | 545 | $2K | |
| 87075 | <1% | 210 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 36 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 827 | $1K |
| 90715 | <1% | 36 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 283 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 39 | $1K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 333 | $996.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 967 | $900.20 |
| 86901 | <1% | 72 | $813.08 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 26 | $720.73 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 39 | $540.26 |
| 73130 | <1% | 37 | $449.36 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,785 | $360.12 |
| 86618 | <1% | 37 | $340.60 | |
| 73562 | <1% | 28 | $314.01 | |
| 73110 | <1% | 40 | $306.69 | |
| 93041 | <1% | 553 | $305.88 | |
| 86617 | <1% | 24 | $278.82 | |
| 83605 | <1% | 68 | $223.31 | |
| 85379 | <1% | 66 | $217.30 | |
| 86038 | <1% | 42 | $211.00 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 91 | $207.47 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,250 | $200.61 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 113 | $195.94 |
| 74018 | <1% | 27 | $149.44 | |
| 72100 | <1% | 12 | $144.56 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 704 | $144.36 |
| 73030 | <1% | 12 | $93.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 200 | $81.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 378 | $55.00 |
| 92551 | <1% | 15 | $45.08 | |
| 87205 | <1% | 14 | $42.06 | |
| 87040 | <1% | 46 | $39.56 | |
| 84702 | <1% | 13 | $37.47 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 103 | $34.52 |
| 86308 | <1% | 14 | $33.36 | |
| 73564 | <1% | 12 | $24.00 | |
| 81015 | <1% | 12 | $16.40 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 345 | $10.84 |
| 90461 | <1% | 269 | $10.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 28 | $5.64 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 263 | $3.60 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 37 | $1.80 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 30 | $1.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12 | $1.21 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 16 | $0.00 |
| 90723 | 0% | 14 | $0.00 | |
| 90648 | 0% | 140 | $0.00 | |
| 99173 | 0% | 51 | $0.00 | |
| 90670 | 0% | 94 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOAKLEY, JEFFERY (CEO AND PRESIDENT)